In today’s ACT Brief, we examine why the future of AI in trials is a trusted orchestration system rather than a single model, how coordinators rate eSource-enabled workflows, and what a bipartisan bill proposes for reusable trial networks.
|Articles|November 1, 2006
- Applied Clinical Trials-11-01-2006
- Volume 0
- Issue 0
eShowcase: iPlan Flow
Software disentangles delivery efficacy from drug efficacy, improving trial results
Advertisement
Software disentangles delivery efficacy from drug efficacy, improving trial results
BrainLab AG (Chicago, IL) has developed a system that allows targeted drug delivery into the brain for treating tumors, a technology that the company says could improve the results of drug trials and ultimately enhance the chances of regulatory approval during trials.
iPlan Flow
iPlan Flow addresses a difficult challenge, since the tight coating of blood vessels protects the brain and prevents fluids from entering it. Delivering enough drug concentration to specific brain cells is therefore problematic due to varying fluid dynamics. The technology uses magnetic resonance imaging to develop a three-dimensional image of the patient's brain. Then, it calculates the drug's distribution patterns, enabling a surgeon to identify the proper locations to place fluid delivery catheters. Potential applications include chemotherapy, gene therapy, molecular-targeted therapy, immunotherapy, and radio-immunotherapy.
BrainLab AG, (800) 784-7700,
Articles in this issue
almost 20 years ago
Building Your Clinical IT Teamalmost 20 years ago
Tough Trials Ahead for Europe's Drug Industryalmost 20 years ago
Experts Urge Major Overhaul at FDAalmost 20 years ago
Recruitment & Consent in Indiaalmost 20 years ago
Pharmacogenomics Enters the Japanese Marketalmost 20 years ago
Meet the EAB: Somesh Nigamalmost 20 years ago
Merging eHR & EDC Conferencealmost 20 years ago
Deploying Mobile Devices in Clinical Trials: Part Twoalmost 20 years ago
eShowcase: Clintrace 4.1almost 20 years ago
eShowcase: PharmaReady V3.0Advertisement
Related to this article
The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, argues that CROs must act as orchestrators rather than aggregators—and that the real test of any AI ecosystem is whether it reduces sponsor coordination burden or just hands it back to them.
Syneos Health and Optum outline a joint model for trial planning, recruitment and site access, with no financial terms or timelines disclosed.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
2
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
3
Bipartisan Bill Would Build Reusable Clinical Trial Networks, With a Focus on Rare Disease
4
Where AI Governance in Clinical Development Falls Short
5